Royalty Pharma: Funding, Investors & Team (Sep 2026)
Royalty Pharma has built a successful business in the biopharmaceutical industry by acquiring revenue-generating intellectual property, primarily royalty interests in biopharmaceutical products that are already on the market or in late-stage development. Rather than developing or selling products themselves, Royalty Pharma provides cash to IP owners and takes on the risks and rewards of ownership. Since 1996, the company has partnered with research institutions, inventors, and biotech and pharma companies, and currently owns interests in 44 approved products and seven in clinical trials or under review by the FDA and EMA.
Royalty Pharma has raised $1.5B across 1 funding round on record, the most recent an undisclosed round of $1.5B announced in Jun 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Royalty Pharma Company Profile and Key Stats
Latest funding round on record: Jun 2024.
Royalty Pharma Funding Rounds
Royalty Pharma Founders and Leadership Team
Contact details for the Royalty Pharma team: 1 of 1 has an email address on file.
Start 14-day free trial →Royalty Pharma Funding Compared to Other Biotechnology Startups
Royalty Pharma's latest round of $1.5B is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Royalty Pharma in Biotechnology and New York
Companies Similar to Royalty Pharma
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Royalty Pharma Funding FAQs
What does Royalty Pharma do?
Royalty Pharma has built a successful business in the biopharmaceutical industry by acquiring revenue-generating intellectual property, primarily royalty interests in biopharmaceutical products that are already on the market or in late-stage development. Rather than developing or selling products themselves, Royalty Pharma provides cash to IP owners and takes on the risks and rewards of ownership. Since 1996, the company has partnered with research institutions, inventors, and biotech and pharma companies, and currently owns interests in 44 approved products and seven in clinical trials or under review by the FDA and EMA.
How much funding has Royalty Pharma raised?
Royalty Pharma has raised $1.5B across 1 round on record. The most recent is an undisclosed round of $1.5B announced in Jun 2024.
When did Royalty Pharma last raise funding?
Royalty Pharma's most recent funding round on record is an undisclosed round of $1.5B, announced in Jun 2024.
Who founded Royalty Pharma?
FundedIQ lists Pablo Legoretta (Founder) at Royalty Pharma.
Where is Royalty Pharma headquartered?
Royalty Pharma is based in New York, United States.
How many employees does Royalty Pharma have?
Royalty Pharma is in the 51-100 employee band.
How does Royalty Pharma's funding compare to other Biotechnology startups?
Royalty Pharma's latest round of $1.5B is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Royalty Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Royalty Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.